Clinical Validation and Treatment Plan Evaluation Based on Autodelineation of the Clinical Target Volume for Prostate Cancer Radiotherapy

被引:6
|
作者
Shen, Jing [1 ]
Tao, Yinjie [1 ]
Guan, Hui [1 ]
Zhen, Hongnan [1 ]
He, Lei [1 ]
Dong, Tingting [1 ]
Wang, Shaobin [2 ]
Chen, Yu [2 ]
Chen, Qi [2 ]
Liu, Zhikai [1 ,3 ]
Zhang, Fuquan [1 ]
机构
[1] Peking Union Med Coll Hosp, Dept Radiat Oncol, Beijing, Peoples R China
[2] MedMind Technol Co, Radiotherapy Tech Dev Dept, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, 1 Shuaifuyuan Wangfujing, Beijing 100730, Peoples R China
关键词
prostate cancer radiotherapy; convolutional neural networks; clinical target volume; deep learning; DVH dosimetric index; RADIATION-THERAPY; SEGMENTATION; DELINEATION; ORGANS; RISK; CT;
D O I
10.1177/15330338231164883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeClinical target volumes (CTVs) and organs at risk (OARs) could be autocontoured to save workload. This study aimed to assess a convolutional neural network for automatic and accurate CTV and OARs in prostate cancer, while comparing possible treatment plans based on autocontouring CTV to clinical treatment plans. MethodsComputer tomography (CT) scans of 217 patients with locally advanced prostate cancer treated at our hospital were retrospectively collected and analyzed from January 2013 to January 2019. A deep learning-based method, CUNet, was used to delineate CTV and OARs. A training set of 195 CT scans and a test set of 28 CT scans were randomly chosen from the dataset. The mean Dice similarity coefficient (DSC), 95th percentile Hausdorff distance (95HD), and subjective evaluation were used to evaluate the performance of this strategy. Predetermined evaluation criteria were used to grade treatment plans, and percentage errors for clinical doses to the planned target volume (PTV) and OARs were calculated. ResultsThe mean DSC and 95HD values of the defined CTVs were (0.84 +/- 0.05) and (5.04 +/- 2.15) mm, respectively. The average delineation time was < 15 s for each patient's CT scan. The overall positive rates for clinicians A and B were 53.15% versus 46.85%, and 54.05% versus 45.95%, respectively (P > .05) when CTV outlines from CUNet were blindly chosen and compared with the ground truth (GT). Furthermore, 8 test patients were randomly chosen to design the predicted plan based on the autocontouring CTVs and OARs, demonstrating acceptable agreement with the clinical plan: average absolute dose differences in mean value of D2, D50, D98, Dmax, and Dmean for PTV were within 0.74%, and average absolute volume differences in mean value of V45 and V50 for OARs were within 3.4%. ConclusionOur results revealed that the CTVs and OARs for prostate cancer defined by CUNet were close to the GT. CUNet could halve the time spent by radiation oncologists in contouring, demonstrating the potential of the novel autocontouring method.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Automated Extraction of Dose/Volume Statistics for Radiotherapy-Treatment-Plan Evaluation in Clinical-Trial Quality Assurance
    Gong, Yutao U. T.
    Yu, Jialu
    Pang, Dalong
    Zhen, Heming
    Galvin, James
    Xiao, Ying
    FRONTIERS IN ONCOLOGY, 2016, 6
  • [32] CT-guided intracavitary radiotherapy for cervical cancer: Comparison of conventional point a plan with clinical target volume-based three-dimensional plan using dose-volume parameters
    Shin, KH
    Kim, TH
    Cho, JK
    Kim, JY
    Park, SY
    Park, SY
    Kim, DY
    Chie, EK
    Pyo, HR
    Cho, KH
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (01): : 197 - 204
  • [33] Radiotherapy for cervix carcinomas: Clinical target volume delineation
    Gnep, K.
    Mazeron, R.
    CANCER RADIOTHERAPIE, 2013, 17 (5-6): : 486 - 492
  • [34] Rectal volume changes during treatment: the case for ansisotropic safety margins around the clinical tumor volume in radiotherapy for prostate cancer
    Linero, D.
    Dipascuale, G.
    Lozano, J.
    Ares, C.
    Nouet, P.
    Escude, L.
    Molla, M.
    Rouzaud, M.
    Miralbell, R.
    EJC SUPPLEMENTS, 2007, 5 (04): : 291 - 292
  • [35] Stereotactic body radiotherapy for prostate cancer: treatment approaches and clinical outcomes
    Miralbell, Raymond
    JOURNAL OF RADIOSURGERY AND SBRT, 2011, 1 (02): : 147 - 154
  • [36] Development and Clinical Introduction of Automated Radiotherapy Treatment Planning for Prostate Cancer
    Winkel, D.
    Bol, G. H.
    van Asselen, B.
    Hes, J.
    Scholten, V.
    Kerkmeijer, L. G. W.
    Raaymakers, B. W.
    MEDICAL PHYSICS, 2016, 43 (06) : 3652 - 3653
  • [37] Development and clinical introduction of automated radiotherapy treatment planning for prostate cancer
    Winkel, D.
    Bol, G. H.
    van Asselen, B.
    Hes, J.
    Scholten, V.
    Kerkmeijer, L. G. W.
    Raaymakers, B. W.
    PHYSICS IN MEDICINE AND BIOLOGY, 2016, 61 (24): : 8587 - 8595
  • [38] New technologies for the radiotherapy of prostate cancer - A discussion of clinical treatment programs
    Meyer, J. L.
    Leibel, S.
    Roach, M.
    Vijayakumar, S.
    IMRT, IGRT, SBRT: ADVANCES IN THE TREATMENT PLANNING AND DELIVERY OF RADIOTHERAPY, 2007, 40 : 315 - 337
  • [39] Target volume margins for lung cancer: Internal target volume/clinical target volume
    Jouin, A.
    Pourel, N.
    CANCER RADIOTHERAPIE, 2013, 17 (5-6): : 428 - 433
  • [40] A critical evaluation of the planning target volume for 3-D conformal radiotherapy of prostate cancer
    Tinger, A
    Michalski, JM
    Cheng, A
    Low, DA
    Zhu, R
    Bosch, WR
    Purdy, JA
    Perez, CA
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (01): : 213 - 221